Age1

About the fund

Age1 Fund I is an early-stage venture fund dedicated to advancing the frontier of longevity biotechnology, investing in companies that target the biological mechanisms of aging as a means to prevent and delay the onset of chronic disease. Positioned at the intersection of cutting-edge science and long-horizon capital, the firm backs founders developing therapeutics, platforms, and tools aimed at extending healthy human lifespan rather than treating individual conditions in isolation. With roots in the broader Longevity Fund ecosystem, age1 reflects a conviction that aging itself is the most important—and addressable—risk factor in healthcare, and that breakthroughs in this domain will redefine both medicine and the economics of global health.

Limited PartnersNext50 Foundation